Table 1 Summary of findings from studies included in the meta-analysis
From: Cell therapy for retinal degenerative disorders: a systematic review and three-level meta-analysis
Author | Year | Condition | Number of eyes | Female percentage | Maximum follow-up | Dosage | Application method | Cells | Type of stem cell | Scaffold or cell suspension | Wet or dry AMD |
|---|---|---|---|---|---|---|---|---|---|---|---|
Song [87] | 2015 | AMD | 2 | 0% | 52w | NA | Subretinal injection | RPE | ESC | Cell suspension | dry |
Song [87] | 2015 | SMD | 2 | 0% | 52w | NA | Subretinal injection | RPE | ESC | Cell suspension | NA |
Park [85] | 2015 | AMD | 2 | NA | 6m | NA | Intravitreal injection | BMSC | ASC | Cell suspension | dry |
Park [85] | 2015 | SMD | 2 | NA | 6m | NA | Intravitreal injection | BMSC | ASC | Cell suspension | NA |
Limoli [50] | 2016 | AMD | 36 | 64% | 6m | NA | Suprachoroidal injection | ADSC | ASC | Cell suspension | dry |
Cotrim [110] | 2017 | AMD | 10 | NA | 3m | NA | Intravitreal injection | BMSC | ASC | Cell suspension | dry |
Kumar [107] | 2017 | AMD | 30 | 37% | 6m | NA | Intravitreal injection | BMSC | ASC | Cell suspension | dry |
Da Cruz [109] | 2018 | AMD | 2 | 50% | 12m | NA | Subretinal implant | RPE | ESC | Cell sheets on human-vitronectin-coated polyester membrane | wet |
Kashani [46] | 2018 | AMD | 4 | 75% | over 6m | NA | Subretinal implant | RPE | ESC | Cell sheets on parylene membrane | dry |
Liu [9] | 2018 | AMD | 3 | 67% | 12m | 10^6/100ul | Subfoval injection | RPE | ESC | Cell suspension | wet |
Oner [70] | 2018 | AMD | 4 | 25% | 6m | NA | Suprachoroidal | ADSC | ASC | Cell suspension | dry |
Oner [70] | 2018 | SMD | 4 | 50% | 6m | NA | Suprachoroidal | ADSC | ASC | Cell suspension | NA |
Heier [43] | 2019 | AMD | 21 | NA | 12m | 3*10^5/50ul | Subretinal injection | UMSC | ESC | Cell suspension | dry |
Cotrim [33] | 2020 | SMD | 10 | 60% | 6m | NA | Intravitreal injection | BMSC | ASC | Cell suspension | NA |
Nittala [105] | 2020 | AMD | 11 | 18% | 12m | NA | Subretinal injection | NSC | ASC | Cell suspension | dry |
Sung [104] | 2020 | SMD | 3 | 0% | 36m | NA | Subretinal injection | RPE | ESC | Cell suspension | NA |
Kashani [108] | 2021 | AMD | 15 | 60% | 12m | NA | Subretinal implant | RPE | ESC | Cell sheets on parylene membrane | dry |
Li [106] | 2021 | SMD | 7 | 100% | 60m | NA | Subretinal injection | RPE | ESC | Cell suspension | NA |
Tuekprakhon [103] | 2021 | RP | 14 | 43% | 12m | gp1, 10^6 gp2, 5*10^6 gp3, 10^7 | Intravitreal injection | BMSC | ASC | Cell suspension | NA |
WiÄ…cek [102] | 2021 | RP | 30 | 40% | 12m | NA | Intravitreal injection | BMSC | ASC | Cell suspension | NA |
Brant Fernandes [111] | 2023 | SMD | 12 | 75% | 12m | 10^6/100ul | Subretinal injection | RPE | ESC | Cell suspension | NA |